Tempus ECG-Low EF vs Zio XT ECG Monitoring System
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary goal is to quickly screen for potential low left ventricular ejection fraction (LVEF) in patients aged 40 or older using a standard 12-lead ECG within a clinical diagnostic setting. This tool is ideal for aiding clinicians in identifying at-risk heart failure patients who may require further, more definitive cardiac evaluation.
View Tempus ECG-Low EF →Choose Zio XT ECG Monitoring System if…
Choose Zio XT ECG Monitoring System if you need extended, continuous ambulatory cardiac monitoring for up to 14 days to detect and diagnose intermittent arrhythmias in patients. This wearable, lead-free biosensor is optimal for patients requiring monitoring outside of a hospital setting, allowing for normal daily activities while providing comprehensive data for expert review.
View Zio XT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | Zio XT ECG Monitoring System |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Integrates with current ECG platforms and electronic health records (EHRs). | Cloud-based (AWS EC2 platform), no on-premise hardware required. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio XT ECG Monitoring SystemTool B, the Zio XT ECG Monitoring System, emphasizes patient comfort and high compliance through its wearable, wire-free, and water-resistant design for continuous monitoring. While Tool A integrates into clinician workflows, Tool B's focus on patient-centric usability for extended wear makes it more broadly user-friendly for its intended purpose.
Clinical Value
Tempus ECG-Low EFTool A, Tempus ECG-Low EF, offers significant clinical value by using AI to detect signs of low Left Ventricular Ejection Fraction (LVEF) from routine 12-lead ECGs, aiding in early identification of patients at risk for heart failure. This capability provides a crucial screening tool for a silent, serious condition, potentially enabling earlier intervention. While Tool B is excellent for diagnosing intermittent arrhythmias through continuous monitoring, Tool A's ability to derive novel, high-impact insights from a standard test gives it an edge in broad screening utility.
Pricing & Value
Zio XT ECG Monitoring SystemTool B, the Zio XT ECG Monitoring System, provides greater pricing transparency by offering specific cost examples for the UK and proposed US Medicare rates. In contrast, Tool A only states 'contact vendor' for pricing, making it more difficult for potential customers to assess its value proposition without direct inquiry.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering Business Associate Agreements (BAAs). Tool A integrates into existing healthcare facility workflows, while Tool B offers a scalable cloud-based deployment without on-premise hardware. Both approaches are robust and well-suited for adoption within healthcare enterprises.
Innovation
Tempus ECG-Low EFTool A, Tempus ECG-Low EF, represents a significant innovation by utilizing AI to extract novel and critical information (risk of low LVEF) from a standard 12-lead ECG, a task traditionally requiring more complex imaging. This transforms a routine diagnostic into a powerful screening tool for a major cardiovascular condition. While Tool B innovates in wearable technology for extended monitoring, Tool A's ability to derive new, high-value insights from existing data through AI is a deeper technological breakthrough.
Support & Docs
Zio XT ECG Monitoring SystemTool B, the Zio XT ECG Monitoring System, offers more comprehensive and transparent support, including 24/7 customer care via phone and email, dedicated patient and provider resources, and readily accessible Instructions for Use (IFU) and Clinical Reference Manuals in multiple languages. Tool A provides email and business-hours phone support, but lacks the explicit 24/7 availability and extensive online documentation of Tool B.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | Zio XT ECG Monitoring System |
|---|---|---|
| Product Name | Tempus ECG-Low EF | Zio XT ECG Monitoring System |
| Company | Tempus AI | iRhythm Technologies |
| Core Function/Purpose | FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. | Wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis. |
| ECG Type & Monitoring Duration | 12-lead ECG recordings; resting, non-ambulatory | Wearable single-lead ECG biosensor; continuous ambulatory cardiac monitoring for up to 14 days |
| Target Condition Detected | Signs associated with low Left Ventricular Ejection Fraction (LVEF u226440%) | Arrhythmia detection and diagnosis |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and Zio XT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-Low EF or Zio XT ECG Monitoring System
Backers
Who funded each tool's parent company.